NCT00063713已完成2 期
A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 152
- 试验地点
- 64
研究概览
简要总结
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
详细描述
VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (64)
Loading locations...
相似试验
终止
2 期
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell LymphomaFollicular LymphomaNCT00136591Lymphoma Study Association87
进行中（未招募）
1 期
A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell LymphomaFollicular LymphomaEUCTR2005-000734-21-BEGroupe d'Etude des Lymphomes de l'Adulte (GELA)
终止
2 期
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC FeaturesCarcinoma, Non-Small-Cell LungAdenocarcinoma, Bronchiolo-AlveolarNCT00117351Millennium Pharmaceuticals, Inc.
已完成
2 期
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT00531453Millennium Pharmaceuticals, Inc.98
进行中（未招募）
不适用
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation.EUCTR2006-006050-10-CZJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium97